Dicerna Pharmaceuticals
75 Hayden Avenue
Lexington
Massachusetts
02421
United States
Tel: 617-621-8097
Website: http://www.dicerna.com/
About Dicerna Pharmaceuticals
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.
Stock Exchange: NASDAQ
Stock Symbol: DRNA
At Dicerna, we interfere to silence genes, fight rare diseases, enhance health and advance science. The goal is to leverage our GalXC™ platform and strategic partnerships to get the drug to the patient as quickly as possible. Dicerna is dedicated to our patients and committed to breaking down barriers that slow progress in rare diseases. Dicerna promotes a “no walls” philosophy that fosters a collaborative culture where all employees are valued and respected. Dicerna interferes to help patients and change lives.
325 articles about Dicerna Pharmaceuticals
-
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
8/5/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys
-
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
8/2/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021.
-
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
7/29/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (IND) application for DCR-AUD, the Company’s investigational RNAi candidate for the treatment of alcohol use disorder (AUD).
-
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
7/21/2021
Dicerna Pharmaceuticals, Inc. today announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0 and 6.
-
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2021
7/1/2021
Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted stock units to be distributed to one new employee with a grant date of July 1, 2021.
-
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
6/22/2021
Dicerna Pharmaceuticals, Inc. announced it has initiated patient dosing in the Company’s Phase 2 ESTRELLA trial of belcesiran, an investigational GalXC™ RNAi therapeutic candidate for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD).
-
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
6/16/2021
Dicerna Announces today announced it has completed dosing in the Company’s PHYOX™4 single-dose safety and tolerability study of its investigational candidate, nedosiran.
-
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
6/3/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference
-
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
5/27/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (“FDA”) acceptance of the Investigational New Drug (“IND”) application filed by Eli Lilly and Company
-
This is the second IND to come out of the two companies’ collaboration. They will initiate a Phase I trial of the drug in cardiometabolic diseases.
-
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement
5/24/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has accepted a GalXC™ RNAi candidate for advancement under the existing agreement between the companies
-
Dicerna to Participate in Upcoming Investor Conferences - May 12, 2021
5/12/2021
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences
-
Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update
5/6/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.
-
Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021
4/29/2021
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Company will release its first quarter 2021 financial results after market close on Thursday, May 6, 2021.
-
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
4/8/2021
– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments
-
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2021
4/1/2021
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted stock units to be distributed to one new employee with a grant date of April 1, 2021.
-
Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies
3/30/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene targets across the central nervous system (CNS) and to specific CNS cell types
-
Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress
3/24/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna, will present new nonclinical data discussing the Company’s GalXC-Plus™ RNAi technology as part of the sixth annual Oligonucleotide and Precision Therapeutics (OPT)
-
Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021
3/11/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will host a webinar on its recently announced alcohol use disorder (AUD) candidate, DCR-AUD. The event will take place on March 18, 2021 at 4:30 p.m. ET
-
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection
3/4/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that Roche has initiated RG6346 in a Roche-sponsored Phase 2 combination trial for the treatment of chronic hepatitis B virus (HBV) infection.